

KMT2A +MRD Assay & Software

When decisions are critical, we have the key to confidence.

The LeukoStrat® KMT2A + MRD Assay is a quantitative digital PCR (dPCR) assay for use with the Roche Digital LightCycler® System. The assay simultaneously detects four key AML-associated KMT2A gene rearrangements (KMT2Ar), enabling both efficient screening and high-resolution measurable residual disease (MRD) assessment using RNA from peripheral blood and bone marrow specimens. With a broad RNA input range, and exceptional sensitivity down to 5×10^{-5} , the assay is a powerful tool to identify prognostic biomarkers and support informed decision-making.

The comprehensive LeukoStrat® KMT2A + MRD Assay includes a single primer probe mix and controls – everything needed for a streamlined workflow. The required LeukoStrat® KMT2A + MRD Software generates objective results in seconds, reporting the detected KMT2Ar and KMT2Ar:ABL1 ratio, which normalizes the target molecules against a stable control gene facilitating reliable and accurate quantitation.

The assay and software combined are a powerful tool for confident KMT2Ar detection in AML.

Identify key KMT2Ar associated with AML

MLLT3 (AF9), MLLT10 (AF10), ELL, and MLLT4/
AFDN (AF6) – fusion partners with implications



All-in-One Solution

Single assay delivers high-sensitivity detection down to 5×10^{-5} for screening and MRD



Objective Accuracy You Can Trust

Strengthen confidence in every decision with software that ensures accurate analyses of complex data



Streamlined Workflow

Harness the power of dPCR to accelerate your results



Learn more about
the assay



Learn more about
the software

invivoscribe.com


10222 Barnes Canyon Rd., Bldg. 1
San Diego, CA 92121, USA
Tel +1 858.224.6600 | Fax +1 858.224.6601
inquiry@invivoscribe.com

 **invivoscribe®**

The Digital LightCycler® System is a registered trademark of Roche.
For Research Use Only (RUO). Not intended for diagnostic purposes.


M-0200 Rev. 01 | January 2026

Workflow



Precise Screening and MRD Results

Absolute quantification from 0.005% to 25% that delivers trustworthy results for dual applications.



Ordering Information

Catalog #	Product Description	Quantity
1100003	LeukoStrat® KMT2A + MRD Assay	32 reactions
S100011	LeukoStrat® KMT2A + MRD Software	1-Year License



The Digital LightCycler® System is a registered trademark of Roche.
For Research Use Only (RUO). Not intended for diagnostic purposes.

M-0200 Rev. 01 | January 2026

invivoscribe.com

10222 Barnes Canyon Rd., Bldg. 1
San Diego, CA 92121, USA
Tel +1 858.224.6600 | Fax +1 858.224.6601
inquiry@invivoscribe.com

Distributed by Abacus dx

1800 ABACUS (AUS) 0800 222 170 (NZ) | info@abacusdx.com | www.abacusdx.com

abacus dx